CD133 表达与胃癌的化疗耐药和早期复发相关。

CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.

机构信息

Division of Gastrointestinal Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

J Surg Oncol. 2012 Dec;106(8):999-1004. doi: 10.1002/jso.23178. Epub 2012 Jun 4.

DOI:10.1002/jso.23178

PMID:22674531

Abstract

BACKGROUND

CD133 has been suggested to be a cancer stem cell (CSC) marker in various types of cancers. The present study assessed the relationship between CD133 expression and clinicopathological features of gastric cancer. In addition, the prognostic value of CD133 for gastric cancer was evaluated.

METHODS

In total, 100 advanced gastric cancer patients who received curative gastrectomy and adjuvant chemotherapy were included. CD133 expression was determined by immunohistochemistry and clinicopathological results, including survival, were analyzed.

RESULTS

CD133 was expressed in 23% of advanced gastric cancer patients (23/100). CD133 expression was significantly associated with serosal exposure (P = 0.036), venous invasion (P = 0.047), well and moderate differentiation (P = 0.002), and intestinal-type Lauren classification (P = 0.001). CD133-positive patients had a significantly worse 5-year disease-free (28.1% vs. 65.8%, P = 0.002) and overall (47.5% vs. 74.0%, P = 0.037) survival rate than those who were CD133-negative. A multivariate analysis suggested that CD133 expression significantly affected the 5-year disease-free and overall survival.

CONCLUSIONS

CD133 may play an important role in chemoresistance and recurrence, thus representing a promising predictive marker for the prognosis of gastric cancer.

摘要

背景

CD133 已被认为是多种类型癌症中的癌症干细胞 (CSC) 标志物。本研究评估了 CD133 表达与胃癌临床病理特征之间的关系。此外，还评估了 CD133 对胃癌的预后价值。

方法

共纳入 100 例接受根治性胃切除术和辅助化疗的晚期胃癌患者。采用免疫组织化学法检测 CD133 表达，并分析其与生存等临床病理结果的关系。

结果

在 100 例晚期胃癌患者中，有 23%（23/100）表达 CD133。CD133 表达与浆膜暴露（P=0.036）、静脉侵犯（P=0.047）、高-中分化（P=0.002）和肠型 Lauren 分类（P=0.001）显著相关。CD133 阳性患者的 5 年无病生存率（28.1% vs. 65.8%，P=0.002）和总生存率（47.5% vs. 74.0%，P=0.037）明显低于 CD133 阴性患者。多因素分析表明，CD133 表达显著影响 5 年无病生存率和总生存率。